TENS improved the athletic ability of CFL injury rats. حسب Min Miao (142697)

الموضوعات:

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  حسب Beatrice T. Nganso (4114768)

الموضوعات:

TENS inhibited inflammation of CFL injury rats by regulating the IL-1 حسب Min Miao (142697)

الموضوعات:

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. حسب Ryan J. Treves (13527735)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... حسب Luke R. Cavanah (19022435)

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

Fig 17 - حسب Jianbo Jia (717814)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات: